News Bavarian Nordic has found its new CEO Six months after Paul Chaplin said he was stepping down as CEO of Bavarian Nordic, the Danish biopharma has named Tarja Stenvall to the role.
News Bayer's Kerendia gets broader use in diabetic kidney disease Bayer's fast-growing Kerendia has had its label extended in the US to include chronic kidney disease associated with type 1 diabetes.
News NICE finally backs Enhertu for HER2-low breast cancer Almost three years after Enhertu was made available in Scotland, the drug is finally an option for patients in England with HER2-low breast cancer.
News Wales takes UK lead on needle-free anaphylaxis prevention Wales has recommended ALK's EURneffy nasal spray as a needle-free option for emergency treatment of severe allergic reactions, including anaphylaxis.
News Legend Biotech names ex-Novartis exec as CEO Cell therapy developer Legend Biotech has named Ingrid Zhang as its new chief executive, ending its search for new leadership.
News FDA backs Curium's Bexlutry as 1st 'radioligand equivalent' Curium's copycat version of Novartis GEP-NET therapy Lutathera, Bexlutry, is the first radioligand equivalent (RLE) to be approved by the FDA.
Oncology On GDF-15 neutralisation and cachexia, with CatalYm As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
